<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066712</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GDCL003</org_study_id>
    <nct_id>NCT04066712</nct_id>
  </id_info>
  <brief_title>Renal PK Study of LC350189</brief_title>
  <official_title>A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of LC350189 in Subjects With Varying Degrees of Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the
      effect of renal impairment on the PK and PD of LC350189.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC from time 0 to the last quantifiable concentration</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacokinetic Assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to 24 hours post dose</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacokinetic Assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 to the end of the dosing interval at steady state</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacokinetic Assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacokinetic Assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration at steady state</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacokinetic Assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum observed plasma concentration</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacokinetic Assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum observed plasma concentration at steady state</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacokinetic Assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of drug excreted in urine (Ae) over each collection interval</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacokinetic Assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum mean concentration over 24 hours</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed effect</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum effect</measure>
    <time_frame>Before dosing on Days 1 through Day 8</time_frame>
    <description>Pharmacodynamic Assessments (uric acid, xanthine, and hypoxanthine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Days 1 through Day 9 (end of study)</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>A: Normal (control) renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Mild impairment renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Moderate impairment renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Severe impairment renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LC350189 200 mg</intervention_name>
    <description>Study drug in capsule form, take two capsules of LC350189 100mg, by oral, once daily, from Day 1 through 7</description>
    <arm_group_label>A: Normal (control) renal function</arm_group_label>
    <arm_group_label>B: Mild impairment renal function</arm_group_label>
    <arm_group_label>C: Moderate impairment renal function</arm_group_label>
    <arm_group_label>D: Severe impairment renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  The subject has a BMI of 18 to 40 kg/m2, inclusive, at screening.

          -  The subject is able to provide written informed consent.

        For healthy subjects only : The subject has normal renal function as determined by eGFR and
        calculated using the MDRD formula, or by 24-hour urine creatinine clearance (CLcr)
        corrected for body size.

        For subjects with renal impairment only

        : The subject has mild, moderate, or severe renal impairment as determined by eGFR and
        calculated using the MDRD formula.

        Exclusion Criteria

          -  The subject has a history or clinical manifestations of a significant neurological,
             cardiovascular, endocrine, gastrointestinal, pulmonary, hematologic, immunologic, or
             psychiatric disease that would preclude study participation, as judged by the
             investigator.

          -  The subject has nephrotic syndrome, defined as serum albumin &lt;3.0 g/dL and urine
             protein/creatinine ratio &gt;350 mg/mmol (as an estimate of approximate proteinuria of
             &gt;3.5 g/day) at screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jieun Lee</last_name>
    <phone>+82-2-6987-4156</phone>
    <email>jieunl@lgchem.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Bell</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

